In this umbrella review of 60 meta-analyses of 1751 RCTs, GLP-1 RAs were associated increased GI adverse events (eg, nausea/vomiting); suggested protective associations with respiratory diseases and serious infections require further confirmation.

This meta-analysis evaluates the reported outcomes of glucagon-like peptide-1 (GLP-1) receptor agonists beyond glycemic control, weight management, and cardiorenal protection and assesses the credibility of the evidence.